Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- IRCCS Ospedale San Raffaele - Neurology and Neurophysiology UnitMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele
- Trial code
- NCT07720765
- Record updated
- 22 July 2026
- Original description
OCt.IN.N is a national, monocentric, prospective, observational cohort study evaluating the utility and applicability of Optical Coherence Tomography (OCT) in the diagnostic workup and longitudinal monitoring of neurological diseases.Read full original descriptionShow less
A National, Monocentric, Prospective Cohort Study to Evaluate the Utility and Applicability of Optical Coherence Tomography in Neurological Clinical Practice
OCt.IN.N is a national, monocentric, prospective, observational cohort study evaluating the utility and applicability of Optical Coherence Tomography (OCT) in the diagnostic workup and longitudinal monitoring of neurological diseases.
840 patients with Central Nervous System neurological diseases (Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, migraine/headache) and 210 age-matched healthy controls will undergo OCT examination at baseline and at 6, 12, 18, and 24 months of follow-up at IRCCS San Raffaele Hospital, Milan, Italy.
OCT is a non-invasive, rapid, and reproducible technique that automatically measures the thickness of individual retinal layers. Retinal layer thicknesses and their longitudinal changes will be correlated with established clinical scales, neuroimaging, and biological markers used in routine neurological practice.
Inclusion: Diagnosis of a Central Nervous System neurological disease (inflammatory diseases such as Multiple Sclerosis; neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease; migraine/headache) according to currently accepted diagnostic criteria for each condition; Age greater than 18 years; Signed informed consent to study participation; Willingness and ability to undergo all study visits and procedures; Absence of neurological disease; Age greater than 18 years; Signed informed consent to study participation; Willingness and ability to undergo all study visits and procedures.
Exclusion: For specific imaging modes using clearly visible light sources (MultiColor, FA, BAF): diagnosis of epilepsy or history of previous epileptic seizures; Presence of any condition that, in the investigators' opinion, renders the subject unsuitable for the study; Presence of any condition that, in the investigators' opinion, renders the subject unsuitable for the study; Refusal to participate or withdrawal of informed consent; Known or confirmed ocular pathology identified during examination (ophthalmological evaluation may be requested at the investigators' discretion); Inability to understand instructions given by investigators; Refusal to participate or withdrawal of informed consent; Known or confirmed ocular pathology identified during examination; Inability to understand instructions given by investigators.